Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.
Dr. Tim Kelly, Vice President, Biopharmaceutical Development of KBI Biopharma, Durham N.C., will describe their work on L-DOS47 formulation development. Dr. Kelly's presentation, entitled "Case Study: Novel Protein Therapeutics, Formulation Development for L-DOS47," will take place at 12:00 p.m., EDT on October 14. KBI Biopharma provides Helix formulation support and conducts analytical and stability studies on L-DOS47 cGMP materials.
"It is a pleasure to see Dr. Kelly being invited to the forum," said Heman Chao, chief scientific officer of Helix BioPharma. "It is an exciting opportunity to showcase formulation and analytical method development work completed on the L-DOS47 compound to our industry peers."
Study highlights global fertility decline and its implications for the future